NEWS– category –
-
Notice regarding selection for the Drug Discovery Venture Ecosystem Enhancement Project (Drug Discovery Venture Public Offering)
HISHOH Biopharma Inc. (Headquarters: Chuo-ku, Tokyo; President and CEO: Joji Hayashida; hereinafter "the Company"), which is working on the development of next-generation allergy immunotherapy with the vision of "A world without allergies," announced that its project, "Next-generation TLR4 agonist HSO-001 for house dust mite allergic rhinitis... -
Notice Regarding Executive Personnel Changes and Transition to a Company with a Board of Directors
HISHOH Biopharma Inc. (Headquarters: Chuo-ku, Tokyo; President and Representative Director: Joji Hayashida; hereinafter "the Company"), which is engaged in the development of next-generation allergy immunotherapy with the vision of "Toward a World Free of Allergies," based on the resolution at the ordinary general meeting of shareholders held on June 24, 2026, established a board of directors on the same date... -
Notice of Appointment of New Directors at HISHOH Biopharma
HISHOH Biopharma Inc. is pleased to announce that Mr. George Hayashida has assumed the position of Director, effective September 2025. Mr. Hayashida has a proven track record in both research and development and business strategy within the pharmaceutical and biotech sectors, particularly in the global medical innovation field... -
Execution of a license agreement for a substance with immunostimulatory properties and implementation of a third-party allocation of new shares in the seed round
HISHOH Biopharma Inc. enters into license agreement for substance with immunostimulatory activity and secures approximately 250 million yen through seed round third-party allotment of shares. HISHOH Biopharma Inc. (Representative Director and President: Naoki Sakurai, Location: Chuo-ku, Tokyo...).
1